Substance P
Pain / InflammationAlso known as: SP, Neurokinin A
Mechanism
An 11-amino acid neuropeptide that transmits pain signals, triggers inflammation, and controls the vomiting reflex. It's one of the oldest known neuropeptides (discovered in 1931). Elevated Substance P levels are found in fibromyalgia, IBS, and depression. Drugs that block its receptor (NK1 antagonists like aprepitant/Emend) are used as powerful anti-nausea medications during chemotherapy.
Technical detail
Undecapeptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) of the tachykinin family. Primary endogenous ligand for NK1R (neurokinin-1 receptor), a Gq-coupled GPCR. Released from C-fiber sensory neurons (pain transmission), enteric neurons (GI motility), and central neurons (mood/emesis). Pain: released at dorsal horn synapses, facilitates nociceptive signaling and central sensitization via NK1R on projection neurons. Neurogenic inflammation: released from peripheral sensory nerve terminals → vasodilation, plasma extravasation, mast cell degranulation ('axon reflex'). Emesis: activates NK1R in nucleus tractus solitarius and area postrema. Mood: NK1R knockout mice show anxiolytic/antidepressant phenotype. NK1R antagonists: aprepitant (Emend, FDA 2003) and fosaprepitant for chemotherapy-induced nausea. Substance P levels elevated 3x in CSF of fibromyalgia patients (Russell et al., 1994).
Effects
## Substance P — System-by-System Effects ### Pain/Nociceptive System (Primary) - **Pain neurotransmitter**: Substance P is an 11-amino acid neuropeptide of the tachykinin family. It is the primary neurotransmitter in C-fiber pain signaling, transmitting pain signals from the periphery to the spinal cord dorsal horn. [Tier 1 — established neuroscience] - **Neurogenic inflammation**: Substance P release from sensory nerve endings causes vasodilation, plasma extravasation (edema), and mast cell degranulation. This "neurogenic inflammation" is distinct from immune-mediated inflammation and explains why pain and inflammation often co-occur. [Tier 1] - **Central pain sensitization**: Substance P in the spinal cord contributes to central sensitization — the amplification of pain signals that leads to chronic pain. When substance P is chronically elevated, normal stimuli become painful (allodynia) and painful stimuli become more painful (hyperalgesia). [Tier 1] - **NK1 receptor**: Substance P acts through the neurokinin-1 (NK1) receptor. NK1 receptors are found in brain, spinal cord, peripheral nerves, immune cells, gut, and vasculature. [Tier 1] ### Immune/Inflammatory System - **Immune cell activation**: Substance P activates macrophages, lymphocytes, mast cells, and dendritic cells. It promotes pro-inflammatory cytokine release (IL-1, IL-6, TNF-α). [Tier 1] - **Mast cell degranulation**: Direct mast cell activation, releasing histamine and other inflammatory mediators. This links neuropeptide signaling to allergic-type inflammation. [Tier 1] - **Wound healing**: Substance P promotes wound healing through fibroblast proliferation, angiogenesis, and immune cell recruitment. This is a beneficial pro-inflammatory role. [Tier 2] ### Gastrointestinal System - **Enteric nervous system**: Substance P is a major neurotransmitter in the enteric nervous system (the "gut brain"). It stimulates GI motility, secretion, and vasodilation. [Tier 1] - **Inflammatory bowel disease**: Elevated substance P in gut tissue contributes to IBD pathology. [Tier 2] - **Nausea and vomiting**: Substance P/NK1 signaling in the brainstem emetic center mediates nausea. This is why NK1 antagonists (aprepitant) are powerful anti-emetics. [Tier 1] ### Psychological/Mood System - **Depression and anxiety**: Substance P/NK1 signaling is involved in stress responses, anxiety, and depression. NK1 receptor antagonists showed antidepressant effects in early clinical trials, though subsequent trials were inconsistent. [Tier 2] - **Stress response**: Substance P is released during psychological stress. It modulates the HPA axis and interacts with CRH (corticotropin-releasing hormone). [Tier 2] - **PTSD**: Elevated substance P has been found in PTSD patients. May contribute to hyperarousal and re-experiencing symptoms. [Tier 2] ### Dermatological System - **Neurogenic skin inflammation**: Substance P in skin nerves causes flushing, edema, and itch. Contributes to rosacea, eczema, and psoriasis pathology. [Tier 2] - **Wound healing**: Promotes skin wound healing through fibroblast and endothelial cell activation. [Tier 2] - **Hair growth**: Substance P may stimulate hair follicle growth. Some dermatological research interest. [Tier 3] ### Respiratory System - **Airway inflammation**: Substance P contributes to neurogenic airway inflammation in asthma and chronic cough. [Tier 2] - **Bronchoconstriction**: Causes airway smooth muscle contraction and mucus secretion. [Tier 1]
Practitioner Guide
## Substance P — Practitioner Guide ### Clinical Profile Substance P is an endogenous neuropeptide with wide-ranging roles in pain, inflammation, immunity, mood, and GI function. Its primary clinical relevance is as a target for ANTAGONISM (blocking), not supplementation. Understanding substance P biology helps practitioners manage pain, nausea, inflammation, and mood disorders. ### Clinical Applications: NK1 Receptor Antagonists #### Aprepitant (Emend) / Fosaprepitant — Anti-Emetic - **FDA-approved**: Prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea/vomiting (PONV) - **Mechanism**: Blocks NK1 receptors in the brainstem emetic center - **Clinical impact**: Addition of aprepitant to standard anti-emetic regimens (5-HT3 antagonist + dexamethasone) significantly reduces CINV, particularly delayed nausea - **The story**: NK1 antagonists were initially developed as antidepressants and analgesics. They failed in those indications but proved remarkably effective as anti-emetics. This is one of the great drug repurposing stories. [Tier 1] #### NK1 Antagonists for Depression (The Failed Promise) - Merck's MK-869 (aprepitant) showed antidepressant effects in a Phase 2 trial (Kramer et al., 1998, Science). This generated enormous excitement about substance P and depression. - Subsequent Phase 3 trials failed to show consistent antidepressant effects. - The field moved on, but the biology is real — substance P IS involved in mood regulation. The failure may have been pharmacological (insufficient brain penetration at studied doses) rather than biological. [Tier 2] ### How Substance P Knowledge Informs Clinical Practice #### Chronic Pain Management - **Central sensitization**: When substance P is chronically elevated in the spinal cord, patients develop central sensitization. This explains why chronic pain often becomes disproportionate to tissue damage. - **Clinical implication**: Treatments that reduce central substance P/NK1 signaling (gabapentinoids, certain antidepressants, TENS, meditation) may be more effective than peripheral pain treatments for chronic pain. - **Fibromyalgia**: Elevated cerebrospinal fluid substance P is one of the most replicated findings in fibromyalgia research (Russell et al., 1994). This supports the central sensitization model of fibromyalgia. #### Neurogenic Inflammation - **Clinical presentation**: Redness, swelling, warmth, and pain that appears disproportionate to the stimulus, often in a dermatomal or nerve-territory distribution. - **Conditions**: Migraine, cluster headache, complex regional pain syndrome (CRPS), rosacea, neurogenic bladder pain. - **Treatment approach**: CGRP antagonists (for migraine) address a related neuropeptide pathway. Capsaicin (depletes substance P from nerve endings) is a direct substance P-targeting treatment. #### Capsaicin — The Substance P Depletion Strategy - **Mechanism**: Capsaicin activates TRPV1 receptors on C-fibers, causing initial substance P release (burning sensation) followed by depletion and defunctionalization of the nerve terminal. - **Clinical use**: Topical capsaicin patches (Qutenza 8%) are FDA-approved for postherpetic neuralgia. Low-concentration OTC creams used for arthritis and neuropathic pain. - **Key insight**: The initial burning is actually substance P release. Repeated application depletes substance P stores, providing analgesia. [Tier 1] ### Substance P as a Biomarker - **Fibromyalgia**: CSF substance P levels are consistently elevated. Could aid diagnosis but CSF sampling is impractical for routine use. - **Stress assessment**: Blood substance P levels increase with psychological stress. Potential biomarker for stress load. - **Chronic pain**: Elevated substance P in various compartments (CSF, joint fluid, blood) correlates with pain severity in some conditions. ### Why Substance P Is NOT Used as a Therapeutic Peptide - Exogenous substance P would cause pain, inflammation, nausea, and immune activation — all undesirable - The goal is to REDUCE substance P signaling in most clinical scenarios - Exception: Topical substance P has been explored for wound healing (leveraging its tissue repair properties), but this is not established practice - Some research interest in substance P for corneal nerve regeneration and wound healing applications [Tier 3]
Research Summary
## Substance P — Research Summary ### Tier 1 (Strong Clinical Evidence) - **Neuroscience**: Substance P as a pain neurotransmitter, its role in neurogenic inflammation, and NK1 receptor signaling are textbook neuroscience with thousands of publications. - **NK1 antagonists for CINV**: Aprepitant and fosaprepitant are FDA-approved with extensive Phase 3 RCT data for chemotherapy-induced and postoperative nausea prevention. - **Capsaicin analgesia**: Topical capsaicin (substance P depletion) is FDA-approved for postherpetic neuralgia. Mechanism is well-characterized. - **Fibromyalgia CSF levels**: Elevated CSF substance P in fibromyalgia is one of the most replicated biomarker findings (Russell et al., 1994, and numerous subsequent studies). - **Central sensitization**: Substance P's role in spinal cord pain amplification is well-established. ### Tier 2 (Moderate Evidence) - **Depression/mood**: Substance P/NK1 involvement in mood regulation is biologically supported. Clinical translation (NK1 antagonists as antidepressants) failed in Phase 3 but the biology remains relevant. - **Wound healing**: Substance P's role in promoting wound healing through fibroblast and immune cell activation is documented in preclinical and small clinical studies. - **IBD**: Elevated substance P in inflammatory bowel disease tissue is documented. Therapeutic targeting is being explored. - **PTSD**: Elevated substance P in PTSD patients documented in several studies. Causal vs. biomarker role is being investigated. - **Neurogenic skin conditions**: Substance P involvement in rosacea, eczema, psoriasis pathology is supported by multiple studies. ### Tier 3 (Emerging) - **Corneal nerve regeneration**: Topical substance P + IGF-1 for corneal nerve regeneration after surgery. Small studies showing promise. - **Hair growth**: Preliminary evidence for substance P stimulating hair follicle growth. - **Cancer biology**: Substance P/NK1 signaling may promote tumor growth in some cancer types. NK1 antagonists being explored as adjunct cancer therapy. ### Key Research Gaps - Whether better NK1 antagonists (improved brain penetration) would succeed where earlier antidepressant attempts failed - Therapeutic substance P applications (wound healing, corneal repair) need larger trials - NK1 antagonists for chronic pain need better clinical development - The neuro-immune interface mediated by substance P is incompletely understood